Rahul K. Verma
Scientist C
Department of Science and Technology
Institute of Nanotechnology
India
Biography
Educational Qualification: ♦ Ph.D., Pharmaceutical Sciences. Pharmaceutics division, Central Drug Research Institute (CDRI), Lucknow, India (2009-2013) ♦ M.S.(Pharm.)., National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India (2003-2005) ♦ B. Pharmacy., Ram-Eesh institute of Technology, Greater NOIDA, India (1999-2003) ♦ Postgraduate Diploma in Intellectual Property Rights- IGNOU, New Delhi (2012) Positions Held : ♦ Scientist-C in Institute of Nano Science and Technology (INST), Mohali, Punjab, India.(April 2014 to Present) ♦ Postdoctoral Researcher- Oklahoma University, Oklahoma City, OK, USA (March 2013- March 2014) ♦Senior Research Fellow- Central Drug Research Institute (CDRI), Lucknow, India (August 2009 to February 2014) ♦ Research Assistant- Central Drug Research Institute (CDRI), Lucknow, India (January 2007 to August 2009) ♦Senior Research Fellow- Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India (September 2005 to November 2006). Honors and Awards : ◊ Royal Society of United Kingdom Fellowship UK- CSIR, INDIA-2009-10 – received to work in UK at Institute of pharmaceutical Innovation (IPI) Bradford University in year 2009-10. ◊ Director’s Special CDRI incentive award-2008. ◊ Bioencapsulation Research Group (BRG)- France travel Award 2009- received to travel and present at Groningen University, THE NETHERLANDS ◊ Bioencapsulation Research Group (BRG)- France travel Award 2008- received to travel and present at Dublin City University, Dublin, IRELAND. ◊ CSIR-SRF – Qualified Senior Research Fellowship-2009 (Council of Scientific & Industrial Research (CSIR), INDIA. ◊ Post Graduate fellowship from NIPER during MS (Pharm) course (2003-2005) ◊ GATE (Graduate Aptitude Test for Engineering) - Qualified in Pharmaceutical Sciences -2004.organized by Indian Institute of Technology (IIT), INDIA.
Research Interest
◊ Our research is aimed at developing safe, efficient, and clinically viable nanoparticulate delivery systems and biomaterials for receptor based targeting, controlled release and depot effect of therapeutic agents/vaccine to their site of action. ◊ Development of antigen and adjuvant loaded nano-carrier systems for nasal mucosal immunization. Designing of nitric oxide releasing nanocarriers for therapy of infectitious diseases like tuberculosis, leishmaniasis. ◊ Delivery of therapeutic agents for the treatment of lung and systemic diseases via dry powder inhalation (DPIs), particularly for tuberculosis and lung cancer. ◊ In vitro and in vivo evaluation of novel drug delivery platforms, preclinical drug evaluation in cell lines animal models.
Publications
-
Dubey PK, Singodia D,Verma RK and Vyas SP (2011) RGD modified albumin nanospheres for tumour vasculature targeting, Journal Pharmacy and Pharmacology, 63(1): 33-40
-
Dwivedi P, Kansal S, Sharma M, Shukla R, Verma AK, Shukla P, Tripathi P, Gupta PK, Saini D,Verma RK, Dwivedi AK and Mishra PR (2012) Exploiting 4-sulphate N-acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytes in vitro and in vivo. Journal of Drug Targeting, 20 (10): 883-96.
-
Pandya S, Verma RK, and Misra A (2011) Nanoparticles Containing Nitric Oxide Donor with Antileishmanial Agent for Synergistic Effect Against Visceral Leishmaniasis. Journal Biomedical Nanotechnology. 7: 213-215
-
Singodia D, Verma A,Verma RK, and Mishra PR (2012) Investigations on Alternate Approach to Target Mannose Receptors on Macrophages using 4-Sulfated N-Acetyl Galactosamine more Efficiently as Compared to Mannose Decorated Liposomes : An Application in Drug Delivery. Nanomedicine - Nanotechnology, Biology and Medicine. 8(4): 468-477.
-
Verma RK, Tripathy RK, Paul MK, Nayyar A, Jain R and Mukhopadhayay AK (2013) Bacterial DNA gyrase is not the target of quinoline based anti-tubercular compounds International Research journal of Pharmacy. 4(1): 284-292.
-
Verma RK, Singh AK, Mohan M, Agrawal AK, and Misra A (2011) Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug delivery systems. Therapeutic Delivery. 2(6): 753-768.
-
Verma RK, Pandya S, and Misra A (2011) Loading and Release of Amphotericin-B from Biodegradable Poly (lactic-co-glycolic acid) Nanoparticles Journal Biomedical Nanotechnology. 7: 118-120.
-
Verma RK, Kaur J, Kumar K, Yadav AB and Misra A (2008) Intracellular time course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary delivery of inhalable Microparticles to Mice. Antimicrobial Agents and Chemotherapy. 52(9): 3195-3201.
-
Verma RK, Mukker JK, Singh RSP, Kumar K, Verma PRP and Misra A (2012) Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to Rhesus macaques. Molecular Pharmaceutics. 9(4): 1011-1016.
-
Verma RK, Singh AK, Mohan M, Agrawal AK, Verma PRP, Gupta A and Misra A (2012) Inhalable Microparticles Containing Nitric Oxide Donors: Saying NO to Intracellular Mycobacterium Tuberculosis. Molecular Pharmaceutics. 9(11): 3183-3187.
